



Product Information

Roar PLTP Activity Assay Kit, 250 assays

Phospholipid Transfer Protein Activity Assay Kit

Catalog No. P7700

U.S. Pat. No. 7,618,784

Assay Method:	Fluorometric
Number of Assays:	250 assays in 0.1 ml assay volume
Kit Contents:	Donor particle: 0.75 ml Acceptor particle: 12.5 ml Assay buffer: 5 ml 10X
Storage and Handling:	Donor particle: store at room temperature Acceptor particle: store at 4°C If stored properly, components are stable for up to 1 year. DO NOT FREEZE.
Instrumentation:	Fluorescence spectrophotometer: cuvette or microplate reading formats. Excitation: 465 nm / Emission: 535 nm.

Overview

Phospholipid transfer protein (PLTP) is a protein present in normal human plasma. PLTP transfers phospholipids among lipoproteins in plasma. The **Roar PLTP Activity Assay Kit** includes proprietary substrates to detect PLTP mediated transfer of fluorescent substrate. Transfer activity results in increased fluorescent emission intensity from the assay.

Advantages

- A rapid, homogeneous, sensitive assay for PLTP activity measurement in plasma
- Assay components stable for up to 1 year
- Interassay coefficient of variation: 3%¹⁸
- High tolerance to DMSO

Materials Required, But Not Supplied

Fluorescence microplate reader appropriate wavelength capabilities (Ex: 465 nm; Em: 535 nm)

Black microtiter plates

37°C water bath / incubator

PLTP source: plasma or serum (fresh or frozen)

Please contact us for more information or to request a complete protocol

P7700 Cited References

Roar PLTP Activity Assay Kit

1. Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. *Atherosclerosis* [in press, accepted manuscript, available online april 17 2009]. **2009**. 10.1016/j.atherosclerosis.2009.04.011.
2. Henderson RJ, Leon CG, Wasan KM. Differences in human phospholipid transfer protein activity following incubation of fungizone compared to lipid-based amphotericin-B formulations in normolipidemic and hyperlipidemic plasma. *Drug Dev Ind Pharm*. **2009**;1-8. 10.1080/03639040902824852.
3. Schlitt A, Blankenberg S, Bickel C, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: The AtheroGene study. *J Lipid Res*; *J Lipid Res*. **2009**;50(4):723-729. <http://www.jlr.org/cgi/content/abstract/50/4/723>. 10.1194/jlr.M800414-JLR200.
4. Gautier T, Klein A, Deckert V, et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. *J Biol Chem*. **2008**;283(27):18702-18710.
5. Thornton SJ, Wong E, Lee SD, Wasan KM. Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: Implications for cholesterol metabolism. *Lipids in Health and Disease*. **2008**;7:21.
6. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC. Macrophage phospholipid transfer protein deficiency and ApoE secretion: Impact on mouse plasma cholesterol levels and atherosclerosis. *Arterioscler Thromb Vasc Biol*. **2007**;27(1):190-196.
7. Schlitt A, Heine GH, Jiang XC, et al. Phospholipid transfer protein in hemodialysis patients. *Am J Nephrol*. **2007**;27(2):138-143.
8. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. *Eur J Clin Invest*. **2006**;36(4):224-230.
9. Klein A, Deckert V, Schneider M, et al. Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: Relevance in phospholipid transfer protein-deficient mice. *Arterioscler Thromb Vasc Biol*. **2006**;26(9):2160-2167.
10. Patankar N, Wasan KM. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations. *Pharm Res*. **2006**;23(5):1020-1024.
11. Lee JY, Timmins JM, Mulya A, et al. HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. *J Lipid Res*. **2005**;46(10):2233-2245.
12. Roy S, Hyogo H, Yadav SK, et al. A biphasic response of hepatobiliary cholesterol metabolism to dietary fat at the onset of obesity in the mouse. *Hepatology*. **2005**;41(4):887-895.
13. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. *J Clin Invest*. **2005**;115(5):1333-1342.
14. Wu MK, Cohen DE. Phosphatidylcholine transfer protein regulates size and hepatic uptake of high-density lipoproteins. *Am J Physiol Gastrointest Liver Physiol*. **2005**;289(6):G1067-74.
15. Beyer TP, Schmidt RJ, Foxworthy P, et al. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: Effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. *J Pharmacol Exp Ther*. **2004**;309(3):861-868.
16. Schneider M, Verges B, Klein A, et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. *Diabetes*. **2004**;53(10):2633-2639.
17. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. *J Lipid Res*. **2003**;44(8):1453-1461.
18. Hudgins LC, Parker TS, Levine DM, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. *J Lipid Res*. **2003**;44(8):1489-1498.
19. Laffitte BA, Joseph SB, Chen M, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. *Mol Cell Biol*. **2003**;23(6):2182-2191.
20. Masson D, Drouineaud V, Moiroux P, et al. Human seminal plasma displays significant phospholipid transfer activity due to the presence of active phospholipid transfer protein. *Mol Hum Reprod*. **2003**;9(8):457-464.
21. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. *Arterioscler Thromb Vasc Biol*. **2003**;23(10):1857-1862.
22. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. *Arterioscler Thromb Vasc Biol*. **2003**;23(9):1601-1607.
23. Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. *J Biol Chem*. **2002**;277(42):39561-39565.

For Research Use Only. Not for Diagnostic or Therapeutic Purposes.

Roar Biomedical, Inc., Audubon Biomedical Center, 3960 Broadway, New York, NY 10032 USA
Tel: +1 (212) 280-2983 ▪ Fax: +1 (212) 280-2968 ▪ info@roarbiomedical.com ▪ www.roarbiomedical.com

©2002-2009 Roar Biomedical, Inc. All rights reserved. This information is subject to change without notice.